Cypress halts trial for sleep apnea therapy
Cypress Bioscience has pulled the plug on its development program for a combination therapy including mirtazapine for sleep apnea. Phase IIa results don't warrant further investigation, researchers say. Cypress and Organon--a division of Akzo Nobel--each conducted independent studies and are now looking at alternatives to continue their collaboration.
- here's the report on Cypress from StreetInsider.com
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
